$100MSeries A, 6 April 2026
Funds take lead ADC STP-100 into early clinical studies, runway into 2029.
- Amount
- $100M
- Stage
- Series A
- Announced
- 6 April 2026
- Lead
- RA Capital Management
- Other investors
- Andreessen Horowitz, Nextech Invest, Emerson Collective, GV, LoLa Capital Partners, GordonMD Global
- Use of funds
- Funds take lead ADC STP-100 into early clinical studies, runway into 2029.
- Checked
- Announced by the company
- Sources
- Stipple Bio debuts with oversubscribed $100M Series A for precision oncology biospace.com
Stipple Bio debuts with oversubscribed $100M Series A for precision oncology fiercebiotech.com